2019-02-13 11:34:08CI   - $187.06
1.95 (1.05%) , IBM - $137.18
1.09 (0.80%) 11:3402/13/19 02/1311:34 02/13/1911:34 | Cigna, Sentara Healthcare expand blockchain-based ecosystem for healthcareIBM (IBM) announced that Cigna (CI) and Sentara Healthcare have joined a new health utility network using blockchain. The aim of the network is to convene a broad ecosystem of healthcare organizations in a highly secure, shared environment with the goal of enabling organizations to build, share and deploy solutions using blockchain that drive digital transformation in the industry. The network also includes Aetna, Anthem, Health Care Service Corporation, and PNC Bank. Together they are exploring ways that blockchain can be used to address a range of industry challenges, including promoting efficient claims and payment processing, enabling secure and frictionless healthcare information exchanges, and ways to maintain current and accurate provider directories. CI - $187.06
1.95 (1.05%) IBM - $137.18
1.09 (0.80%) | |
|---|
- $187.06
1.95 (1.05%) - 01/16/19
- MSCO
Morgan Stanley says UnitedHealth, Walgreens could benefit from CVS-Walmart fight After CVS Health (CVS) announced Walmart (WMT) will leave Caremark's commercial and Managed Medicaid retail pharmacy networks at the end of April 2019, analysts at Morgan Stanley discussed the potential impact of the fight to both companies and to competitors. Analyst Ricky Goldwasser said the dispute "brings back memories" of the Express Scripts (ESRX) and Walgreens (WBA) breakup in 2011, but unlike in that case it is only the early days of the 2019/2020 selling season, not after the selling season concluded. Walmart's plans to leave should have a limited impact on CVS' FY19 EPS power, but adds uncertainty to PBM selling season if not resolved in the near-term, said Goldwasser. Morgan Stanley's Simeon Gutman said that if the dispute is not resolved, it could end up reducing Walmart's EBIT by about $260M in 2019, which he estimates could have a 7c, or 1.5%, impact on EPS. In terms of who may benefit if no resolution is reached, the team estimates both Walgreens and CVS retail could gain an incremental 25 bps of pharmacy share and that UnitedHealth's (UNH) Optum and Cigna (CI) could see a step up in PBM selling season win rates. However, given Walmart's relatively low share, they view the PBM share opportunity as "minimal." - 01/31/19
- MSCO
01/31/19
NO CHANGETarget $391
MSCO
Overweight Anthem price target raised to $391 from $372 at Morgan Stanley Morgan Stanley analyst Zack Sopcak said Anthem's (ANTM) launch of IngenioRx three quarters early, giving it a presence in the 2020 selling season, leads him to see an increased likelihood of gaining share as compared to entry in the 2021 selling season when CVS Health (CVS) and Cigna (CI) would have more time for their marketing messages to mature post their respective mergers. While also noting that Anthem's 2019 guidance for EPS of $19+ came in well above estimates, Sopcak raised his price target on the stock to $391 from $372 and reiterated as a top pick with an Overweight rating. - 02/01/19
- GSCO
02/01/19
NO CHANGEGSCO
Conviction Buy Cigna provided 'much needed clarity' on earnings call, says Goldman Sachs Goldman Sachs analyst Stephen Tanal said Cigna's "extensive details" on its Q4 earnings call provided "much needed visibility" and clarity and boosted his confidence. Rebate guarantees are not expected to be a headwind in 2019 and the company does not expect the proposed rule from HHS to remove the safe harbor for rebates to have a meaningful impact on growth or its earnings trajectory, Tanal tells investors. He reiterates a Buy rating on Cigna shares and keeps it on the firm's Conviction List. - 02/04/19
- PIPR
02/04/19
NO CHANGETarget $227
PIPR
Overweight Piper Jaffray likes the set-up for Cigna shares in 2019 Piper Jaffray analyst Sarah James likes the set-up for Cigna (CI) in 2019. The company has built 25c-50c of conservatism into its earnings guidance and has potential for a "strong" 2020 driven by better cost trend control, its specialty business, and working down the $200M stranded overhead cost from Anthem's departure, James tells investors in a research note. Further, the analyst does not have the pharmacy benefits manager volume coming back in-house from UnitedHealth (UNH) in her numbers yet, which she sees as "likely upside to 2021." The analyst also believes Cigna "screens as cheap" at 10.6 times expected 2020 earnings. James reiterates an Overweight rating on the shares with a $227 price target. - $137.18
1.09 (0.80%) - 01/23/19
- WELS
01/23/19
NO CHANGETarget $140
WELS
Market Perform IBM price target lowered to $140 from $155 at Wells Fargo Wells Fargo analyst Ed Caso lowered his price target for IBM to $140 from $155 to reflect a lower market multiple and the lack of 2020-2021 share repurchase expected, offset by signs of further progress in its digital transition. The analyst reiterates a Market Perform rating on the shares. - 01/23/19
- BMOC
01/23/19
NO CHANGETarget $147
BMOC
Market Perform IBM price target raised to $147 from $145 at BMO Capital BMO Capital analyst Keith Bachman raised his price target on IBM (IBM) to $147 after the company's better than expected Q4 revenues in its "three important business units of Cognitive, GBS and Tech Services." The analyst also contends that while the outlook for FY19 earnings was below consensus, he sees progress on revenues as more important for the company. Bachman adds that he remains constructive on the impact of IBM's pending Red Hat (RHT) deal improving its top line, but does not see the current valuation for IBM as sufficiently compelling for a more constructive view, keeping his Market Perform rating. - 01/31/19
- TIGR
01/31/19
NO CHANGETIGR
Neutral IBM's Cognitive Solutions strength offset by weak System, says Tigress Financial Tigress Financial analyst Ivan Feinseth kept his Hold rating on IBM after another set of mixed results reported for Q4 last week. The analyst notes that the company's strong Cognitive Solutions performance continues to be offset by ongoing weakness in Systems revenue. Feinseth adds that its Business Performance is also trending, but sees IBM "starting to benefit from the growing performance of its Cognitive Solutions and Global Business Services business lines", driven by "growing demand for analytics, IoT, and security services." - 02/11/19
- PIPR
Piper storage survey positive for Pure Storage, Nutanix, NetApp Piper Jaffray conducted its fiscal Q4 Storage Reseller Survey by collecting feedback from 28 resellers and distributors. While only five of 14 vendors had net positive results versus six of the 14 last quarter, the firm saw "strong results" for Pure Storage (PSTG), Rubrik, Nutanix (NTNX), Veeam and NetApp (NTAP), analyst Andrew Nowinski told investors earlier in a research note. Pure Storage also had the strongest pipeline heading into the April quarter, added the analyst. The company's results sharply improved in the survey, with 67% of resellers citing "Above Plan" results, the highest level seen in three years, says Nowinski. The stock in early trading is up 19c to $18.47. Of those surveyed by Piper, 36% of resellers said they saw a negative impact from the U.S. government shutdown, with Dell (DELL), HP/3PAR (HPQ) and IBM (IMB) the most impacted. |